Q-omics provides the consensus-scored MIR1278 profile across patient tissues and cancer cell-line models. MIR1278 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR1278 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, MIR1278 RNA expression shows 6,129 significant gene co-expression associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, STAD, and LUAD as cancer lineages where MIR1278 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1278 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1278 survival associations across molecular data types. MIR1278 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1278 RNA expression–survival associations across cancer types. High MIR1278 expression shows unfavorable associations in SKCM, UVM, STAD, PAAD and BLCA, but favorable associations in LAML. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR1278 RNA expression.
This table summarizes MIR1278 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1278. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1278 shows higher tumor expression in STAD. The STAD box plot shows higher MIR1278 RNA expression in tumor versus normal tissue (log2 FC = +0.485, t-test p = .041).
This table shows molecular features associated with MIR1278 in patient tissues and cancer cell lines. In patient samples, MIR1278 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
